Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
Akito Hata, Nobuyuki Yamamoto(Wakayama Medical University), Kenichi Yoshimura(Hiroshima University), Yoshihito Kogure(Nagoya Medical Center), Hirotaka Matsumoto(Hyogo Prefectural Amagasaki General Medical Center), Taira Ninomaru, Takashi Seto(National Hospital Organization Kyushu Cancer Center), Yuki Sato(Goethe University Frankfurt), Takeshi Sawada(The University of Osaka), Shunichi Sugawara(Sendai Kousei Hospital), Hideaki Okada, Terufumi Kato(Taipei Veterans General Hospital), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Nobuyuki Katakami(Takarazuka City Hospital), Masahide Oki(National Hospital Organization), Takashi Kijima(Hyogo University), Isamu Okamoto(Kyushu University), Toshihide Yokoyama(Kurashiki Central Hospital)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k